Treatment of Antibody-Mediated Rejection in Kidney Transplantation - European Medical Journal

Treatment of Antibody-Mediated Rejection in Kidney Transplantation

Download PDF
Magdalena Durlik

No potential conflict of interest.

EMJ Nephrol. ;1[1]:40-45. DOI/10.33590/emjnephrol/10313514.
Kidney transplantation, antibody-mediated rejection, donor-specific antibodies, management of antibody-mediated rejection, IVIg, plasmapheresis, bortezomib, rituximab, eculizumab

Each article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.


Antibody-mediated rejection (AMR) is a relatively rare but severe complication in kidney transplantation associated with increased risk of graft loss. Diagnosis of acute and chronic AMR is based on typical histological hallmarks, deposition of C4d in peritubular capillaries and presence of donor-specific antibodies (DSA). Many novel and attractive treatment options have become available in recent years: antibody removal and production inhibition (plasmapheresis, IVIg), B cell depletion (rituximab), plasma cell depletion and apoptosis (bortezomib), and complement activation inhibition (eculizumab). Standard therapy is based on PP and IVIg. Preliminary results with new agents are encouraging but require randomised clinical trials and long-term follow-up.

Please view the full content in the PDF above. 

Keep your finger on the pulse

Join Now

Elevating the Quality of Healthcare Globally